During the second quarter, Zelluna moved from preclinical to clinical-stage execution, dosing its first patient with ZI-MA4-1 in July, followed […]
Successful initial public offering
PRESSEMELDING Vellykket børsnotering for Ultimovacs Oslo, 31. mai 2019 Kreftvaksineselskapet Ultimovacs ASA har hentet inn 370 millioner kroner i en […]